Indeed selective RAF inhibitors have demonstrated clear survival benefit in oncogenic BRAF (predominantly the BRAFV600 mutation)-driven melanomas (approximately 50% of patients; [7–10]) and results in near-complete abrogation of MAPK signaling in tumors harboring such mutations [11]. This evidence concerns the gene BRAF and melanoma.